News
1h
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...
AI-designed antibiotics show in vivo efficacy against multidrug-resistant N. gonorrhoeae and MRSA, offering a new approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback